Spectrophotometric method for simultaneous determination of valsartan and substances from the group of statins in binary mixtures

1. M. Lunder, M. Janić, B. Jug and M. Šabovič, The effects of low-dose fluvastatin and valsartan combination on arterial function: A randomized clinical trial, Eur. J. Intern. Med. 23 (2012) 261-266; https://doi.org/10.1016/j.ejim.2011.11.01110.1016/j.ejim.2011.11.011Search in Google Scholar

2. V. Savić, B. Eržen, M. Janić, M. Lunder, M. Boncelj, K. Kanc, A. Janež and M. Šabovič, Improvement of arterial wall characteristics by the low-dose fluvastatin and valsartan combination in type 1 diabetes mellitus patients, Diab. Vasc. Dis. Res. 10 (2013) 420-425; https://doi.org/10.1177/147916411348510210.1177/1479164113485102Search in Google Scholar

3. M. Janić, M. Lunder, M. Prezelj and M. Šabovič, A combination of low-dose fluvastatin and valsartan decreases inflammation and oxidative stress in apparently healthy middle-aged males, J. Cardiopulm. Rehabil. Prev. 34 (2014) 208-212; https://doi.org/10.1097/HCR.000000000000002710.1097/HCR.0000000000000027Search in Google Scholar

4. R. C. Hermida, C. Calvo, D. E. Ayala and J. E. Lopez, OR-6: Administration time-dependent efficacy of valsartan-atorvastatin combination in hyperlipidemic patients with essential hypertension, Am. J. Hypertens. 18 (S4) (2005) 2A; https://doi.org/10.1016/j.amjhyper.2005.03.00610.1016/j.amjhyper.2005.03.006Search in Google Scholar

5. S. A. Hussein, H. M. El-Wadood, M. A. Abdallah and A. A. Khorshed, HPTLC with fluorescence densitometry for simultaneous determination of some angiotensin II receptor blockers in tablets and plasma, J. AOAC Int. 98 (2015) 354-360; https://doi.org/10.5740/jaoacint.14-17910.5740/jaoacint.14-179Search in Google Scholar

6. D. Tsvetkova, D. Obreshkova and S. Ognjanov, Validation of TLC densitometry for simultaneous quality and quantity analysis of angiotensin II receptor antagonist losartan, telmisartan and valsartan, Chim. Pharm. 64 (2011) 39-44.Search in Google Scholar

7. T. Inglot, A. Gumieniczek, L. Komsta and A. Kasinska, LC and principal component analysis in the lipophilicity study of seven angiotensin II-AT1 receptor antagonists (sartans), Chromatographia 68 (2008) 977-983; https://doi.org/10.1365/s10337-008-0801-510.1365/s10337-008-0801-5Search in Google Scholar

8. J. Golubovic, A. Protic, B. Otasevic and M. Zecevic, Quantitative structure-retention relationships applied to development of liquid chromatography gradient-elution method for the separation of sartans, Talanta 150 (2016) 190-197; https://doi.org/10.1016/j.talanta.2015.12.03510.1016/j.talanta.2015.12.035Search in Google Scholar

9. K. C. Skai and A. P. Mazureki, Identification and determination of selected angiotensin II receptor antagonist group drugs by HPLC method, Acta Pol. Pharm. Drug Res. 68 (2011) 831-837. Search in Google Scholar

10. S. Hillaert and W. V. den Bossche, Optimization and validation of a capillary zone electrophoretic method for the analysis of several angiotensin-II-receptor antagonists. J. Chromatogr. A 979 (2002) 323-333; https://doi.org/10.1016/S0021-9673(02)01247-510.1016/S0021-9673(02)01247-5Search in Google Scholar

11. S. Hillaert, T. R. M. De Beer, J. O. De Beer and W. V. den Bossche, Optimization and validation of a micellar electrokinetic chromatographic method for the analysis of several angiotensin-II-receptor antagonists, J. Chromatogr. A 984 (2003) 135-146; https://doi.org/10.1016/S0021-9673(02)01832-010.1016/S0021-9673(02)01832-0Search in Google Scholar

12. S. Zargar and T. A. Wani, New UPLC-MS/MS method for simultaneous determination of telmisartan and hydrochlorthiazide in human plasma, Lat. Am. J. Pharm. 33 (2014) 432-440. Search in Google Scholar

13. E. Şatana, S. Altinay, N. G. Göger, S. A. Özkan and Z. Şentürk, Simultaneous determination of valsartan and hydrochlorothiazide in tablets by first-derivative ultraviolet spectrophotometry and LC, J. Pharm. Biomed. Anal. 25 (2001) 1009-1013; https://doi.org/10.1016/S0731-7085(01)00394-610.1016/S0731-7085(01)00394-6Search in Google Scholar

14. M. M. Deshpande, M. P. Mahajan and S. D. Sawant, Simultaneous estimation of valsartan and hydrochlorothiazide in fixed dose combination in UV spectrophotometry, Int. J. Pharm. Sci. Res. 3 (2012) 236-240.Search in Google Scholar

15. T. A. Wani, A. Ahmad, S. Zargar, N. Y. Khalil and I. A. Darwish, Use of response surface methodology for development of new microwell-based spectrophotometric method for determination of atorvastatin calcium in tablets, Chem. Cent. J. 6 (2012) 134-142; https://doi.org/10.1186/1752-153X-6-13410.1186/1752-153X-6-134Search in Google Scholar

16. I. Muszalska, A. Sobczak, A. Dołhaand and A. Jelińska, Analysis of sartans: A review, J. Pharm. Sci. 103 (2014) 2-28; https://doi.org/10.1002/jps.2376010.1002/jps.23760Search in Google Scholar

17. M. S. Tahir, A. Adnan and Q. Syed, Chromatographic resolution of angiotensin II receptor antagonists (sartans), J. Chromatogr. B 1027 (2016) 57-63; https://doi.org/10.1016/j.jchromb. 2016.05.023Search in Google Scholar

18. A. Nakashima, C. Saxer, M. Niina, N. Masuda, K. Iwasaki and K. Furukawa, Determination of fluvastatin and its five metabolites in human plasma using simple gradient reversed-phase highperformance liquid chromatography with ultra-violet detection, J. Chromatogr. B 760 (2001) 17-25; https://doi.org/10.1016/S0378-4347(01)00250-X10.1016/S0378-4347(01)00250-XSearch in Google Scholar

19. F. P. Gomes, P. L. Garcia, J. M. P. Alves, A. K. Singh, E. R. M. Kedor-Hackmann and M. I. R. M. Santoro, Development and validation of stability-indicating HPLC methods for quantitative determination of pravastatin, fluvastatin, atorvastatin and rosuvastatin in pharmaceuticals, Anal. Lett. 42 (2009) 1784-1804; https://doi.org/10.1080/0003271090306066910.1080/00032710903060669Search in Google Scholar

20. E. Kublin, E. Malanowicz, B. Kaczmarska-Graczyk, K. Czerwińska, E. Wyszomirska and A. P. Mazurek, Development of chromatographic method for determination of drugs reducing cholesterol level - statins and ezetimibe, Acta Pol. Pharm. Drug Res. 72 (2015) 429-437.Search in Google Scholar

21. J. L. Yan, Determination of fluvastatin sodium by differential pulse voltammetry, Pak. J. Biol. Sci. 9 (2006) 2156-2158.10.3923/pjbs.2006.2156.2158Search in Google Scholar

22. M. P. S. Neves, P. A. Nouws and C. Delerue-Matos, Direct electroanalytical determination of fluvastatin in a pharmaceutical dosage form: Batch and flow analysis, Anal. Lett. 41 (2008) 2794-2804; https://doi.org/10.1080/0003271080242188910.1080/00032710802421889Search in Google Scholar

23. G. Ergin, S. Çağlar, A. Önal and S. E. Toker, Spectrophotometric determination of 3-hydroxy-3- methylglutaryl coenzyme-A reductase inhibitors in pharmaceutical preparations, Turk. J. Chem. 37 (2013) 171-181.Search in Google Scholar

24. K. Pasha, S. Muzeeb, S. J. S. Basha, D. Shashikumar, R. Mullangi and N. R. Srinivas, Analysis of five HMG-CoA reductase inhibitors - atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin: pharmacological, pharmacokinetic and analytical overview and development of a new method for use in pharmaceutical formulations analysis and in vitro metabolism studies, Biomed. Chromatogr. 20 (2006) 282-293; https://doi.org/10.1002/bmc.56110.1002/bmc.561Search in Google Scholar

25. S. Ertürk, A. Önal and S. M. Çetin, Analytical methods for the quantitative determination of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in biological samples, J. Chromatogr. B. 793 (2003) 193-205; https://doi.org/10.1016/S1570-0232(03)00314-310.1016/S1570-0232(03)00314-3Search in Google Scholar

26. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, ICH Harmonised Tripartite Guideline, Validation of Analytical Procedures: Text and Methodology Q2(R1), Current Step 4 version, Geneva November 2005; http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q2_R1/Step4/Q2_R1__Guideline.pdf; last access date April 22, 2017.Search in Google Scholar

27. Polish Pharmacopoeia, Xth ed., Office for Registration of Medicinal Products, Medical Devices and Biocidal Products, Warszawa 2016.Search in Google Scholar